A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: TNBC - Triple-Negative Breast Cancer|Ovarian Cancer
Interventions: DRUG: Etrumadenant|DRUG: IPI-549|DRUG: Pegylated liposomal doxorubicin (PLD)|DRUG: nanoparticle albumin-bound paclitaxel (NP)
Sponsor: Arcus Biosciences, Inc.
Collaborators: Infinity Pharmaceuticals, Inc.